Survival Improved With Nivolumab Plus Chemo in Urothelial Carcinoma - report from ESMO2023

Professor Michiel van der Heijden presented the results of CheckMate 901, a phase III trial evaluating the combination of nivolumab plus gemcitabine/cisplatin versus gemcitabine/cisplatin alone for patients with previously untreated unresectable or metastatic urothelial carcinoma. He shares details on the design of the trial and the late-breaking results that he presented at ESMO 2023. Video: https://medicaldigest.org/scientific-contents/interview:survival-improved-nivolumab-plus-chemo-urothelial-carcinoma